Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
1.72% $16.01
America/New_York / 1 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 101.30 mill |
EPS: | 1.840 |
P/E: | 8.70 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 6.33 mill |
Avg Daily Volume: | 0.0216 mill |
RATING 2024-05-01 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 8.70 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.04x |
Company: PE 8.70 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$31.37 (95.91%) $15.36 |
Date: 2024-05-01 |
Expected Trading Range (DAY) |
---|
$ 15.06 - 16.80 ( +/- 5.45%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-09-30 | Bonanni Luciano B | Buy | 3 400 | FONAR CORPORATION COMMON STOCK |
2022-09-29 | Bonanni Luciano B | Buy | 1 300 | FONAR CORPORATION COMMON STOCK |
2022-09-30 | Damadian Timothy Raymond | Buy | 2 200 | FONAR CORPORATION COMMON STOCK |
2022-09-29 | Damadian Timothy Raymond | Buy | 2 500 | FONAR CORPORATION COMMON STOCK |
2018-09-26 | Damadian Raymond V | Sell | 450 | FONAR CORPORATION COMMON STOCK |
INSIDER POWER |
---|
100.00 |
Last 45 transactions |
Buy: 335 680 | Sell: 27 600 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.01 (1.72% ) |
Volume | 0.0138 mill |
Avg. Vol. | 0.0216 mill |
% of Avg. Vol | 63.81 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.